Update On…

Product Update

Michael Smart

drug, chemotherapy
ONF 2008, 35(5), 850-851. DOI: 10.1188/08.ONF.850-851

Jump to a section

    References

    Strausz, J., Rolski, J., Aziz, Z., Guckert, M. E., Wright, R. R., Thorn, S., et al. (2008). Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) [Abstract 20585]. Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings, Part I, 26(19S), 731s.
    Varian Medical Systems. (2008). University of Alabama at Birmingham first in the U. S. to treat cancer patients with RapidArc™ Radiotherapy. Retrieved August 4, 2008, from http://varian.mediaroom.com/index.php?s=43&item=578
    Natanson, C., Kern, S. J., Lurie, P., Banks, S. M., & Wolfe, S. M. (2008). Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death. JAMA, 299(19), 2304-2312.